Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.33 |
| ▸ | FABP7 | O15540 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22444620 | 0.91 | CASP3 (0.36) | CASP3FABP5FABP7NPSR1KMT2A | |
| SCHEMBL22454850 | 0.91 | CASP3 (0.36) | CASP3FABP5FABP7NPSR1KMT2A | |
| SCHEMBL29633912 | 0.91 | CASP3 (0.36) | CASP3FABP5FABP7NPSR1KMT2A | |
| SCHEMBL21837756 | 0.87 | CASP3 (0.40) | CASP3MDM4TP53FABP5FABP7 | |
| SCHEMBL21837754 | 0.87 | CASP3 (0.40) | CASP3MDM4TP53FABP5FABP7 | |
| SCHEMBL30522070 | 0.87 | CASP3 (0.40) | CASP3MDM4TP53FABP5FABP7 | |
| SCHEMBL24579267 | 0.87 | CASP3 (0.40) | CASP3MDM4TP53FABP5FABP7 | |
| SCHEMBL30896033 | 0.87 | CASP3 (0.42) | CASP3MDM4TP53FABP5FABP7 | |
| SCHEMBL29697681 | 0.87 | CASP3 (0.40) | CASP3MDM4TP53FABP5FABP7 | |
| SCHEMBL30054786 | 0.87 | CASP3 (0.40) | CASP3MDM4TP53FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CASP3 3906/4885MDM4 441/4885TP53 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.